Jinxin Fertility Group Limited

DB:3NX Stock Report

Market Cap: €950.6m

Jinxin Fertility Group Valuation

Is 3NX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3NX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3NX (€0.34) is trading below our estimate of fair value (€1.03)

Significantly Below Fair Value: 3NX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3NX?

Key metric: As 3NX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 3NX. This is calculated by dividing 3NX's market cap by their current earnings.
What is 3NX's PE Ratio?
PE Ratio23.3x
EarningsCN¥310.84m
Market CapCN¥7.24b

Price to Earnings Ratio vs Peers

How does 3NX's PE Ratio compare to its peers?

The above table shows the PE ratio for 3NX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.9x
SYAB SYNLAB
27.6x-11.4%€2.5b
V3V VITA 34
27.8x-25.4%€71.8m
FME Fresenius Medical Care
19.5x19.3%€12.9b
RHK RHÖN-KLINIKUM
20.6x7.5%€923.8m
3NX Jinxin Fertility Group
23.3x19.6%€7.7b

Price-To-Earnings vs Peers: 3NX is good value based on its Price-To-Earnings Ratio (23.3x) compared to the peer average (23.9x).

Price to Earnings Ratio vs Industry

How does 3NX's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
3NX 23.3xIndustry Avg. 18.0xNo. of Companies8PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 3NX is expensive based on its Price-To-Earnings Ratio (23.3x) compared to the European Healthcare industry average (18x).

Price to Earnings Ratio vs Fair Ratio

What is 3NX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3NX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.3x
Fair PE Ratio28.5x

Price-To-Earnings vs Fair Ratio: 3NX is good value based on its Price-To-Earnings Ratio (23.3x) compared to the estimated Fair Price-To-Earnings Ratio (28.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 3NX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.34
€0.47
+37.9%
25.1%€0.72€0.36n/a13
Dec ’25€0.35
€0.45
+28.5%
25.4%€0.71€0.35n/a14
Nov ’25€0.39
€0.47
+21.3%
26.3%€0.71€0.35n/a16
Oct ’25€0.41
€0.50
+22.2%
42.3%€1.19€0.35n/a16
Sep ’25€0.27
€0.56
+109.5%
35.0%€1.18€0.35n/a16
Aug ’25€0.29
€0.57
+94.8%
31.6%€1.17€0.38n/a16
Jul ’25€0.32
€0.59
+83.8%
31.3%€1.19€0.40n/a16
Jun ’25€0.36
€0.58
+63.1%
31.3%€1.18€0.40n/a16
May ’25€0.31
€0.58
+87.0%
33.9%€1.18€0.35n/a15
Apr ’25€0.29
€0.72
+151.9%
37.2%€1.38€0.36n/a15
Mar ’25€0.28
€0.74
+161.2%
31.7%€1.37€0.42n/a13
Feb ’25€0.26
€0.80
+208.6%
32.0%€1.37€0.42n/a15
Jan ’25n/a
€0.84
0%
26.5%€1.37€0.52n/a15
Dec ’24n/a
€0.85
0%
26.3%€1.39€0.54€0.3515
Nov ’24€0.45
€0.85
+88.0%
26.3%€1.39€0.54€0.3915
Oct ’24€0.45
€0.87
+94.0%
24.6%€1.38€0.54€0.4115
Sep ’24€0.44
€0.89
+103.5%
22.0%€1.40€0.55€0.2716
Aug ’24€0.52
€0.93
+81.3%
21.3%€1.40€0.56€0.2916
Jul ’24€0.48
€0.94
+95.3%
17.4%€1.34€0.76€0.3214
Jun ’24€0.48
€0.97
+102.3%
17.2%€1.38€0.78€0.3614
May ’24€0.80
€0.99
+24.3%
16.6%€1.40€0.79€0.3114
Apr ’24€0.59
€1.09
+84.3%
22.5%€1.76€0.79€0.2912
Mar ’24€0.77
€1.09
+42.8%
22.1%€1.78€0.80€0.2813
Feb ’24€0.84
€1.11
+31.2%
25.4%€1.86€0.80€0.2611
Jan ’24€0.83
€1.09
+31.0%
27.1%€1.84€0.79n/a11
Dec ’23€0.72
€1.09
+50.0%
27.1%€1.84€0.79n/a11

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:32
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jinxin Fertility Group Limited is covered by 30 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Ethan CuiBofA Global Research
Qianyi LiChina International Capital Corporation Limited